Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cd147 and Cyclophilin A: A Promising Potential Targeted Therapy for Covid-19 and Associated Cancer Progression and Chemo-Resistance Publisher



Bakhtiyari M1, 2 ; Haji Aghasi A3 ; Banihashemi S4 ; Abbassioun A5 ; Tavakol C6 ; Zalpoor H2, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
  2. 2. Network of Immunity in Infection, Malignancy & Autoimmunity (NIIMA), Universal Scientific Education & Research Network (USERN), Tehran, Iran
  3. 3. Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran
  4. 4. Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
  5. 5. Department of Virology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
  6. 6. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Shiraz Neuroscience Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Source: Infectious Agents and Cancer Published:2023


Abstract

Coronavirus disease-2019 (COVID-19), as a worldwide serious issue has been shown to lead to progression and poor outcomes in cancer patients. The underlying mechanisms for SARS-CoV-2 infection’s adverse effects on cancer patients have not been fully understood. We hypothesized that CD147 and Cyclophilin A (CyPA) not only can play a significant role in infection severity but also can contribute to cancer progression and chemotherapy resistance in cancer patients with COVID-19. In addition, we hypothesized that the expression of both CD147 and CyPA could be increased by Hypoxia-inducible Factor-1 alpha (HIF-1α) activation during hypoxic conditions that occurred during COVID-19. Therefore, this evidence can open a new window in the management of cancer patients during the pandemic and therapeutic approaches targeting CD147 and CyPA could be a potentially promising therapeutic approach for such patients. © 2023, The Author(s).
Related Docs
View other Related Docs
1. Hesperetin As an Anti-Sars-Cov-2 Agent Can Inhibit Covid-19-Associated Cancer Progression by Suppressing Intracellular Signaling Pathways, Inflammopharmacology (2022)
2. Hypoxia‐Inducible Factor 1 Alpha (Hif‐1Α) Stimulated and P2x7 Receptor Activated by Covid-19, As a Potential Therapeutic Target and Risk Factor for Epilepsy, Human Cell (2022)
3. Diabetes As One of the Long-Term Covid-19 Complications: From the Potential Reason of More Diabetic Patients’ Susceptibility to Covid-19 to the Possible Caution of Future Global Diabetes Tsunami, Inflammopharmacology (2023)
4. The Roles of Metabolic Profiles and Intracellular Signaling Pathways of Tumor Microenvironment Cells in Angiogenesis of Solid Tumors, Cell Communication and Signaling (2022)
5. The Role of Natural Products As Inhibitors of Jak/Stat Signaling Pathways in Glioblastoma Treatment, Oxidative Medicine and Cellular Longevity (2022)
6. Quercetin As a Jak–Stat Inhibitor: A Potential Role in Solid Tumors and Neurodegenerative Diseases, Cellular and Molecular Biology Letters (2022)
7. The Roles of Eph Receptors, Neuropilin-1, P2x7, and Cd147 in Covid-19-Associated Neurodegenerative Diseases: Inflammasome and Jak Inhibitors As Potential Promising Therapies, Cellular and Molecular Biology Letters (2022)
8. Autophagy Induced by Helicobacter Pylori Infection Can Lead to Gastric Cancer Dormancy, Metastasis, and Recurrence: New Insights, Human Cell (2024)
Experts (# of related papers)
Nima Rezaei (1)
Maryam Nourizadeh (1)
Other Related Docs
9. An Overview on the Treatments and Prevention Against Covid-19, Virology Journal (2023)
10. Immunoediting in Sars-Cov-2: Mutual Relationship Between the Virus and the Host, International Immunopharmacology (2022)